An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

PHASE2TerminatedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Epilepsy
Interventions
DRUG

diazepam nasal spray

Trial Locations (33)

10016

Acorda Site #223, New York

14642

Acorda Site #233, Rochester

19104

Acorda Site #219, Philadelphia

19107

Acorda Site #237, Philadelphia

20817

Acorda Site #202, Bethesda

23298

Acorda Site #215, Richmond

29425

Acorda Site #203, Charleston

30912

Acorda Site #217, Augusta

32308

Acorda Site #231, Tallahassee

32819

Acorda Site #206, Orlando

33592

Acorda Site #241, Port Charlotte

33606

Acorda Site #201, Tampa

33609

Acorda Site #234, Tampa

37232

Acorda Site #218, Nashville

38103

Acorda Site #235, Memphis

46804

Acorda Site #225, Fort Wayne

50010

Acorda Site #226, Ames

53792

Acorda Site #210, Madison

63131

Acorda Site #205, St Louis

64111

Acorda Site #216, Kansas City

72205

Acorda Site #204, Little Rock

75251

Acorda Site #221, Dallas

77030

Acorda Site #229, Houston

85054

Acorda Site #227, Phoenix

90095

Acorda Site #213, Los Angeles

92868

Acorda Site #220, Orange

96817

Acorda Site #232, Honolulu

97239

Acorda Site #230, Portland

98057

Acorda Site #224, Renton

02115

Acorda Site #212, Boston

Acorda Site #214, Boston

02215

Acorda Site #208, Boston

07601

Acorda Site #222, Hackensack

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY